Skip to content
Disclosery

Wildcat Capital Management, LLC

Follow

13F filer, CIK 1582384, NEW YORK, NY

Wildcat Capital Management, LLC reported $145,073,911 across 5 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001999371-25-017707

Period
2025-09-30
Reported value
$145M
Holdings
5
Top 10 weight
100%
New
2
Sold out
3

Largest buys vs the previous quarter

SecurityShares changeApprox. value
TTANnew+4,138$417K
GTLBnew+5,861$264K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RLXreduced-11,628,012-$30.6M
TICexited-1,500,000-$16.6M
URGNexited-495,606-$6.79M
SILEXION THERAPEUTICS CORPexited-113,428-$91.9K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001999371-25-017707, largest first. % of portfolio is the value over $145,073,911, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ULCCFRONTIER GROUP HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 28,061,351 shares; 2024Q4: 28,061,351 shares; 2025Q1: 28,061,351 shares; 2025Q2: 28,061,351 shares; 2025Q3: 28,061,351 shares 28,061,351$124M85.4%0Timeline
RLXRLX TECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 18,046,195 shares; 2024Q4: 18,046,195 shares; 2025Q1: 18,046,195 shares; 2025Q2: 18,046,195 shares; 2025Q3: 6,418,183 shares 6,418,183$16.9M11.64%-11,628,012Timeline
ALLOALLOGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,920,787 shares; 2024Q4: 2,920,787 shares; 2025Q1: 2,920,787 shares; 2025Q2: 2,920,787 shares; 2025Q3: 2,920,787 shares 2,920,787$3.62M2.5%0Timeline
TTANSERVICETITAN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 4,138 shares 4,138$417K0.29%newTimeline
GTLBGITLAB INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 11,399 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 5,861 shares 5,861$264K0.18%newTimeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
TICTIC SOLUTIONS INC1,500,000$16.6Mshares
URGNUROGEN PHARMA LTD495,606$6.79Mshares
SILEXION THERAPEUTICS CORPSILEXION THERAPEUTICS CORP113,428$91.9Kshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001999371-25-017707 base2025-11-14acceptance time not in the bulk data set